We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Polymyxin B-Immobilized Fiber on Blood Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Levels in Acute Respiratory Distress Syndrome Patients.
- Authors
Nakamura, Tsukasa; Kawagoe, Yasuhiro; Matsuda, Takaharu; Shoji, Hisataka; Ueda, Yoshihiko; Tamura, Naoaki; Ebihara, Isao; Koide, Hikaru
- Abstract
Background/Aims: Metalloproteinase (MMP)-9 plays a role in the pathogenesis of acute respiratory distress syndrome (ARDS). Polymyxin B-immobilized fiber (PMX-F) treatment improves circulatory disturbance and oxygenation in ARDS patients. We aimed to assess whether PMX-F treatment alters the blood MMP-9 and tissue inhibitor of MMP (TIMP)-1 levels in ARDS patients. Methods: Twelve ARDS patients who received PMX-F treatment and 20 healthy control volunteers were included in this study. PMX-F was carried out twice at a rate of 100 ml/min for 2 h with a time interval of 24 h. Blood MMP-9 and TIMP-1 levels were measured before and after PMX-F treatment. We monitored blood pressure and the PaO2/FiO2 (PF) ratio before and after PMX-F treatment. Results: The mortality of ARDS patients after PMX-F treatment was 16.7%. Chest X-ray abnormalities were ameliorated in surviving patients after PMX-F treatment. Systolic and diastolic blood pressure increased significantly after PMX-F treatment (p < 0.01). The PF ratio also increased significantly after PMX-F treatment (p < 0.01). Blood MMP-9 and TIMP-1 levels in ARDS patients (126.4 ± 36.4 and 326.5 ± 52.5 ng/ml) were significantly higher than in controls (34.5 ± 12.5 and 160.5 ± 24.5 ng/ml; p < 0.01). PMX-F treatment reduced these levels significantly (the first treatment: MMP-9 85.4 ± 28.6 ng/ml, p < 0.05, TIMP-1 265.8 ± 36.6 ng/ml, p < 0.05; the second treatment: MMP-9 56.5 ± 18.8 ng/ml, p < 0.01, TIMP-1 220.6 ± 30.5 ng/ml, p < 0.01). Conclusion: These data suggest that MMP-9 and TIMP-1 may play a role in the pathogenesis of ARDS and that PMX-F treatment ameliorated increased MMP-9 and TIMP-1 levels in ARDS patients. Copyright © 2004 S. Karger AG, Basel
- Publication
Blood Purification, 2004, Vol 22, Issue 3, p256
- ISSN
0253-5068
- Publication type
Article
- DOI
10.1159/000078494